Stocktoria
MANNKIND CORP MNKD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-07-28
MANNKIND CORP statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% |
| Net margin | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% |
| FCF margin | 3.9% | 11.5% | -4.2% | -88.5% | -97.0% |
| Return on assets | 0.7% | 7.0% | -2.5% | -29.6% | -25.2% |
| Return on equity | -11.5% | -35.0% | 4.8% | 34.9% | 38.7% |
| Debt / equity | -6.95× | -0.46× | -1.09× | -1.09× | -1.34× |
| Current ratio | 1.70 | 3.28 | 3.59 | 3.49 | 4.54 |
| Revenue growth | 22.2% | 43.5% | 99.4% | 32.2% | 15.8% |
Source: SEC EDGAR filings · CIK 0000899460 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.